Brokers Set Expectations for Globus Medical FY2025 Earnings

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research upped their FY2025 EPS estimates for Globus Medical in a research report issued on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $3.43 for the year, up from their previous forecast of $3.42. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $0.97 EPS.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.18. The firm had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. Globus Medical’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period last year, the company earned $0.57 EPS.

Other equities research analysts have also issued research reports about the stock. Truist Financial lifted their price objective on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a report on Thursday, January 9th. Morgan Stanley raised Globus Medical from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. BTIG Research lifted their target price on Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company increased their price target on Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.91.

Globus Medical Trading Up 0.4 %

NYSE:GMED opened at $92.82 on Thursday. The company has a market cap of $12.64 billion, a price-to-earnings ratio of 138.53, a price-to-earnings-growth ratio of 1.78 and a beta of 1.19. Globus Medical has a twelve month low of $49.33 and a twelve month high of $93.67. The stock has a fifty day simple moving average of $84.87 and a 200-day simple moving average of $76.56.

Insiders Place Their Bets

In other Globus Medical news, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Keith W. Pfeil sold 14,167 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,667 shares of company stock worth $6,674,554. 18.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

A number of large investors have recently modified their holdings of GMED. Coldstream Capital Management Inc. raised its position in shares of Globus Medical by 2.2% in the 3rd quarter. Coldstream Capital Management Inc. now owns 6,219 shares of the medical device company’s stock valued at $447,000 after purchasing an additional 131 shares during the last quarter. Stephens Inc. AR raised its holdings in shares of Globus Medical by 3.4% in the third quarter. Stephens Inc. AR now owns 4,229 shares of the medical device company’s stock worth $303,000 after buying an additional 138 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Globus Medical by 2.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company’s stock worth $403,000 after buying an additional 140 shares during the period. Berry Wealth Group LP grew its holdings in shares of Globus Medical by 5.1% during the fourth quarter. Berry Wealth Group LP now owns 3,409 shares of the medical device company’s stock valued at $282,000 after buying an additional 164 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Globus Medical by 60.2% during the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock valued at $45,000 after buying an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.